Rani Therapeutics to Participate in May Investor Conferences

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:

H.C. Wainwright 2nd Annual BioConnect Investor Conference
Location: The Nasdaq Headquarters, New York City
Date: Monday, May 20th at 2:30pm E.T
Format: Fireside Chat and 1×1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran

UBS Spring Biotech Conference
Location: UBS, New York City
Date: Tuesday, May 21st, 2024
Format: 1×1 Investor Meetings

Interested parties can register for and access the live webcast for the H.C. Wainright Conference by visiting the “Events” section of the Rani Therapeutics website. The webcast replay will be available after the conclusion of the presentation.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

investors@ranitherapeutics.com

Media Contact:

media@ranitherapeutics.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.